Vonova.io

Executive Summary

Vonova.io is a San Francisco-based digital health and AI/machine learning company developing a novel, minimally invasive neurovascular access technology. Founded in 2020, Vonova leverages the body's venous system as a natural pathway to the brain, aiming to eliminate the need for invasive skull-drilling procedures. The company focuses on delivering diagnostic and therapeutic solutions for chronic neurological conditions, including chronic subdural hematomas, neuropathic pain, and epilepsy. By combining AI-driven imaging and navigation with a proprietary catheter-based platform, Vonova seeks to improve patient outcomes, reduce recovery times, and lower healthcare costs associated with traditional neurosurgical interventions. The company's approach addresses a significant unmet need in the treatment of neurological disorders, where current treatment options are often invasive, risky, or limited in efficacy. As a private early-stage company, Vonova faces typical development and regulatory hurdles but has strong market potential given the growing prevalence of neurological conditions and demand for less invasive treatments. The company's technology could disrupt the $10B+ neurovascular access market. Key risks include clinical validation, regulatory clearance, and competition from established medical device companies. Near-term catalysts include preclinical data releases, initiation of first-in-human studies, and potential Series A financing to advance product development. With a focused strategy and innovative approach, Vonova is well positioned to attract investor interest and strategic partnerships in the digital health and neurotechnology space.

Upcoming Catalysts (preview)

• Q1 2027Series A Financing Round50% success
• Q2 2027First-in-Human Clinical Trial Initiation30% success
• Q4 2026FDA Breakthrough Device Designation40% success